Immatics has revised the statistical strategy for its pivotal SUPRAME Phase 3 trial of anzu-cel in previously treated advanced melanoma after progression and death events accumulated more slowly than initially modeled across the blinded study. Following recent feedback from the United States Food and Drug Administration, the company now plans to eliminate the previously contemplated interim progression-free survival analysis and proceed directly to a single final PFS analysis during the first half of 2027, while retaining 90% statistical power for the primary endpoint. Immatics will also enroll approximately 90 additional patients, increasing the study population to roughly 450, primarily to strengthen statistical power for the secondary overall-survival endpoint rather than to delay the primary PFS analysis.
The change is potentially important for anzu-cel’s path toward regulatory submission, but the slower event accumulation should be interpreted cautiously. SUPRAME remains blinded, meaning Immatics does not know whether fewer-than-modeled progression or death events are being driven by anzu-cel, the investigator-choice control arm, both groups or other trial assumptions. The adjustment therefore improves the statistical and commercial design of the study without providing new evidence that anzu-cel itself is performing better than expected. Immatics continues to expect topline PFS results in the first half of 2027 followed by a Biologics License Application submission later that year.
SUPRAME will now skip its interim PFS analysis and move directly to one definitive comparison
SUPRAME is a global, randomized and controlled Phase 3 study evaluating anzu-cel, also known as anzutresgene autoleucel or IMA203, against investigator’s choice in patients with unresectable or metastatic melanoma previously treated with a PD-1 immune checkpoint inhibitor. The primary endpoint is progression-free survival assessed by blinded independent central review using RECIST 1.1 criteria, while overall survival, objective response rate, safety and patient-reported quality-of-life measures are important secondary endpoints.
The original design contemplated separate interim and final PFS analyses once specified numbers of progression or death events had occurred. Immatics now says aggregate PFS events are occurring more slowly than originally modeled, prompting the company to replace those two analyses with a single final assessment based on a lower prespecified number of PFS events while still maintaining 90% power for the primary endpoint. The company expects the randomizations required for that final PFS analysis to be completed by year-end 2026.
Moving directly to the final analysis can simplify the statistical framework and avoid spending statistical alpha on an interim look that may provide limited additional value when events are accumulating more slowly. It also reduces the possibility that an inconclusive interim analysis distracts from the definitive outcome, although the final success threshold and full amended statistical plan will ultimately determine how demanding the trial remains.
The approximately 90 additional patients serve a somewhat different purpose. Immatics plans to increase enrollment to roughly 450 participants to strengthen power for overall survival, an endpoint that could materially influence the eventual commercial profile even though PFS remains the primary measure supporting full regulatory approval. The company said the additional enrollment and larger number of OS events required for that secondary analysis will not alter the timing of the final PFS readout.
For a cell therapy entering a competitive melanoma market, stronger overall-survival evidence could become particularly valuable after approval discussions move beyond whether the trial technically meets its primary endpoint. Physicians and payers will ultimately want to understand whether a one-time cellular treatment produces sufficiently durable clinical benefit to justify the logistics and costs associated with individualized TCR T-cell therapy.
Slower progression events are interesting but cannot yet be treated as an anzu-cel efficacy signal
Event-driven oncology trials can take longer than expected when patients across the study remain progression free for longer than assumed during statistical planning. That circumstance can appear encouraging, but in a blinded randomized study it does not identify which treatment is responsible.
The aggregate event slowdown could theoretically reflect stronger anzu-cel activity, better-than-expected results with therapies selected for the control arm, differences in the enrolled patient population or some combination of those factors. Treating slower aggregate events as a hidden positive readout for anzu-cel would therefore go beyond the information currently available.
The earlier Phase 1b results provide the actual efficacy evidence supporting SUPRAME. At the recommended Phase 2 dose, anzu-cel produced a 56% confirmed objective response rate across 32 evaluable metastatic melanoma patients, with median duration of response of 14.6 months, median progression-free survival of 6.1 months and median overall survival of 16.2 months. The 12-month overall-survival rate was 70% and the 24-month rate was 46%.
Among the 14 patients with cutaneous melanoma, the confirmed response rate was 50% and median response duration reached 17.9 months after median follow-up of 18.7 months. Those findings came from a small, single-arm early-stage dataset, making SUPRAME essential for determining whether the apparent activity survives a randomized comparison against contemporary therapies.
Anzu-cel is a PRAME-directed T-cell receptor T-cell therapy engineered to recognize a PRAME-derived peptide presented through HLA-A*02:01 and trigger an antitumor immune response. PRAME is expressed across more than 50 cancer types, giving Immatics a broader strategic interest in validating the target beyond melanoma.
Safety from the Phase 1b melanoma program has so far been described as predictable and manageable. The most frequent treatment-emergent events included cytopenias associated with lymphodepleting chemotherapy, while cytokine release syndrome was predominantly Grade 1 or Grade 2 and immune effector cell-associated neurotoxicity syndrome occurred infrequently and was generally mild. Those observations still require confirmation across the much larger Phase 3 population.
A larger survival analysis could strengthen anzu-cel’s commercial case if PFS succeeds
Immatics is preparing anzu-cel as its first potential commercial PRAME therapy and has already started building infrastructure for a possible launch following regulatory approval. The company now expects the Phase 3 PFS readout during the first half of 2027 and a BLA submission later in 2027, slightly reframing an earlier timetable that had contemplated interim and final analyses before filing.
The company is simultaneously exploring anzu-cel in metastatic uveal melanoma through an additional approximately 30-patient Phase 2 cohort. Data from that cohort and the ongoing Phase 1b study are intended to support a potential label expansion after an initial melanoma approval, if the overall clinical program succeeds.
Immatics is also advancing its second-generation IMA203CD8 PRAME cell therapy across other solid tumors. Phase 1 data presented at the 2026 American Society of Clinical Oncology meeting showed a 63% objective response rate and 50% confirmed response rate in hard-to-treat gynecologic cancers, including four complete responses, while synovial sarcoma patients produced a 67% objective response rate and 64% confirmed response rate. Updated findings are planned for the European Society for Medical Oncology Congress in 2026.
Those programs mean SUPRAME carries significance beyond one product indication. A successful randomized trial would provide important validation for PRAME-directed cellular therapy and strengthen confidence in Immatics’ wider strategy of targeting the antigen through both cell therapies and TCR bispecifics. A negative study would not automatically invalidate the other candidates because their constructs and clinical populations differ, but it would likely raise broader questions around translating impressive early PRAME response rates into controlled late-stage outcomes.
Immatics has $448.2 million to fund the enlarged trial as research spending rises
Immatics reported $448.2 million in cash, cash equivalents and other financial assets at June 30, down from $534.7 million at the end of 2025. The balance includes the benefit of $24.2 million in net proceeds from an at-the-market equity offering, while management continues to project financial runway into 2028.
Second-quarter research and development expenses climbed to $71.1 million from $51.4 million a year earlier, with the increase driven substantially by advancing clinical programs including SUPRAME. General and administrative expenses rose to $15.8 million from $14.6 million as Immatics increased activities associated with potential commercialization, while quarterly collaboration revenue reached $10.4 million. The company posted a second-quarter net loss of $71.2 million compared with $80.1 million a year earlier.
The $448.2 million balance gives Immatics considerable capacity to absorb the additional enrollment planned for SUPRAME without making the amendment primarily a financing question. The company is also funding several PRAME programs simultaneously, however, meaning the final Phase 3 result will influence not only the potential first commercial launch but future capital allocation across a relatively broad clinical portfolio.
Immatics shares were trading around $9.02 on August 18, down approximately 2.5% from the previous close after moving between $8.64 and $10.00 during the session. The company’s market capitalization was approximately $930 million. The modest decline suggests investors are not interpreting the slower PFS event rate as a clear positive efficacy signal and may instead be waiting for the definitive randomized data expected in 2027. That assessment is an inference from the trading pattern rather than a confirmed explanation from shareholders.
The revised SUPRAME strategy therefore appears less like a delay and more like a statistical consolidation around the dataset Immatics ultimately needs. The primary PFS analysis remains scheduled for the first half of 2027, FDA feedback has informed the amended approach and the larger trial should provide stronger overall-survival evidence if anzu-cel succeeds. What the slower event rate actually means for treatment efficacy remains unknowable while the study is blinded, leaving the final Phase 3 comparison as the result that will determine whether the promising early PRAME cell therapy data can support Immatics’ first regulatory filing.
